E-Newsletter - March 2024
General News and Announcements


Alliance Research in the News

Recent Publications
CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma | Cancer Res Commun vol 4 (3) 682-90 2024
http://www.ncbi.nlm.nih.gov/pubmed/38363156

PRESTO: A Phase III, open-label study of Intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19) | J Clin Oncol   JCO2301157 2024
http://www.ncbi.nlm.nih.gov/pubmed/38261983

Lobectomy, segmentectomy or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: a post-hoc analysis of CALGB 140503 (Alliance) | J Thorac Cardiovasc Surg vol 167 (1) 338-347.e1 2024
http://www.ncbi.nlm.nih.gov/pubmed/37473998

Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer | Eur J Cancer vol 201  113914 2024
http://www.ncbi.nlm.nih.gov/pubmed/38359495

HER2 gene expression levels are predictive and prognostic in patients with metastatic colorectal cancer enrolled in CALGB/SWOG 80405 | J Clin Oncol   JCO2301507 2024
http://www.ncbi.nlm.nih.gov/pubmed/38457761

DNA mutational profiling in patients with colorectal cancer treated with standard of care reveals differences in outcome and racial distribution of mutations | J Clin Oncol vol 42 (4) 399-409 2024
http://www.ncbi.nlm.nih.gov/pubmed/37992266

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab | Prostate Cancer Prostatic Dis 2024
http://www.ncbi.nlm.nih.gov/pubmed/38347114

Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG) | Leukemia vol 38 (1) 45-57 2024
http://www.ncbi.nlm.nih.gov/pubmed/38017103

Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance) | Pharmacogenomics J vol 24 (2) 2024
http://www.ncbi.nlm.nih.gov/pubmed/38438359

Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017 | Cancer vol 130 (5) 750-69 2024
http://www.ncbi.nlm.nih.gov/pubmed/37916800

Secondary analysis of the rate of second primary lung cancer from Cancer and Leukemia Group B 140503 (Alliance) trial of lobar versus sublobar resection for T1aN0 non-small-cell lung cancer | J Clin Oncol   JCO2301306 2024
http://www.ncbi.nlm.nih.gov/pubmed/38215351

Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial | J Natl Cancer Inst vol 116 (1) 115-26 2024
http://www.ncbi.nlm.nih.gov/pubmed/37676819

****************

Recent News
AMBASSADOR: Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma
https://ascopost.com/news/january-2024/ambassador-pembrolizumab-in-muscle-invasive-and-locally-advanced-urothelial-carcinoma/

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
https://ascopubs.org/doi/full/10.1200/JCO.23.01157

Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?
https://ascopubs.org/doi/10.1200/JCO.23.02410

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their CombinationA Phase 3 Randomized Clinical Trial
https://jamanetwork.com/journals/jamaoncology/fullarticle/2813940

Alliance for Clinical Trials in Oncology (Alliance) trial A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur)
https://www.researchsquare.com/article/rs-3773522/v1

Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL
https://pubmed.ncbi.nlm.nih.gov/38215395/

Molecular Features of Prostate Cancer After Neoadjuvant Therapy in the Phase 3 CALGB 90203 Trial
https://academic.oup.com/jnci/article-abstract/116/1/115/7263172?redirectedFrom=fulltext&login=false

Hollings Fellow Receives National Grant for Smoking Cessation Aid for Cancer Patients
https://web.musc.edu/about/news-center/2024/02/28/hollings-fellow-receives-national-grant-for-smoking-cessation-aid-for-cancer-patients


*********************************************************************************************************************


Update: Alliance Participant Engagement Portal (PEP)

Learn about how PEP is off to a great start here.


 


*********************************************************************************************************************


2024 Alliance Spring Hybrid Group Meeting

 

 

 

 

 

 

 

 

The 2024 Alliance Spring Hybrid Group Meeting, Wednesday, May 15-Saturday, May 18, will take place in Chicago at the Loews Chicago O'Hare Hotel and virtually.

Registration will open this week (the week of March 18). Formal invitations will only be sent to funded travelers, and those who receive the invitation should RSVP and register through the e-mail. All other attendees should register through the link provided in the Alliance broadcast e-mail that will be sent this week or by visiting the Alliance website. 

>> Virtual attendees will join sessions through Attendee Hub.
>> Self check-in will be utilized again for onsite registration.
>> Meeting hashtag: #AllianceSpring24

 

 

Read more news briefs from this issue: